Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06633783
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-07
Brief Title:
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multicenter Randomized Open-label Parallel-controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy for Weight Loss in Obese Subjects
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to compare the effect on body weight in subjects taking semaglutide injection or subjects taking Wegovy
Detailed Description:
The study will involve participants engaging in discussions with study staff regarding healthy dietary choices strategies for increasing physical activity and additional methods for achieving weight loss alongside the administration of the study medication Participants will be randomly assigned to receive either semaglutide injection or Wegovy The study medication will be administered via a weekly subcutaneous injection using a fine needle in the abdominal skinfold The duration of the study will be approximately 2 years during which participants will attend 13 clinic visits with the study physician
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None